A second round of funding for the amfAR Research Consortium on HIV Eradication (ARCHE) totals more than $1 million, according to a statement from amfAR, The Foundation for AIDS Research. Established in 2010, ARCHE aims its research at eliminating the reservoirs of latent HIV that permit the virus to retain a foothold in the body during antiretroviral therapy. This year's grants include studies of drugs approved by the FDA for other purposes that might prove useful against HIV. Most notable of these is disulfiram, an FDA-approved drug to treat alcoholism. An ARCHE-funded study demonstrated disulfiram's potential to expel the virus from HIV-infected cells in a laboratory setting.

To read the amfAR statement, click here.